Human Metabolome Technologies

HMT’s platform is specifically designed for the quantitative detection of small polar metabolites from a wide range of sample types including blood (whole, plasma, serum, platelets, WBC’s), urine, CSF, cells, and tissues.  Our platform is the only quantitative option available.

HMT has pioneered the use of Capillary Electrophoresis Mass Spectrometry for the separation and quantitation of a wide range of metabolic species.  We are a full-service company providing expertise and knowledge in a wide range of areas including oncology, neurology, immunology, and other metabolic diseases.

Multiple Analysis packages are designed for biomarker discovery, unbiased profiling, targeted analysis, lipid analysis, and Isotope analysis.  Our proprietary software ensures the most accurate data and provides complex statistical analyses.  Our scientific staff provides a biological interpretation and significance.

With HMT’s platform, metabolomics can easily be used for biomarker discovery, drug target discovery and validation, elucidation of active metabolic pathways, and therapeutic efficacy.

Tsutomu (Tom) Hoshiba
Human Metabolome Technologies America, Inc
24 Denby Rd., Suite 217
Boston, MA 02134
(617) 987-0554
Web: Human Metabolome Technologies

Metabolomic Screens are supported with 50% subsidy from the OSTR.


Metabolon’s platform is designed and optimized to detect small molecule biomarkers from numerous chemical classes and various sample matrices (e.g. plasma, serum, urine, CSF, cell extracts, tissues). Analysis by three unique analytical platforms, shown below, separates and detects the broadest range of biochemicals.

  • Separation and detection using three independent platforms
    • LC-MS/MS (+ESI)
    • LC-MS/MS (- ESI)
    • GC-MS
  • Informatics to identify biochemicals
    • Filtering of background noise
    • Comparison of mass spectra to a database of standards
  • Statistics to identify changes
    • p and q values to determine significant biochemical changes

The OSTR has developed a pricing agreement with the company, Metabolon, Inc., to screen biological samples for metabolites using their proprietary methods. Their patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology, and bioprocess optimization.

John Luster
Science Development Director – Mid Atlantic
Metabolon, Inc.
PO Box 110407
Research Triangle Park, NC 27709

Metabolomic Screens are supported with 50% subsidy from the OSTR.